The Association Between Two Polymorphisms in the TYMS Gene and Breast Cancer Risk: a Meta-analysis
Overview
Authors
Affiliations
Thymidylate synthase (TYMS), which catalyzes the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate, is a central enzyme in the folate metabolic pathway. Epidemiological studies have evaluated the association between TYMS gene polymorphisms and breast cancer susceptibility; however, the published data are still inconclusive. To derive a more precise assessment of this relationship, we performed a meta-analysis based on currently available data by searching PubMed, EMBASE databases, and the Cochrane Library. A total of 10 eligible studies were identified for the TYMS TSER polymorphism (six studies with 2,718 cases and 3,423 controls) and for the TYMS TS3'-UTR polymorphism (five studies with 1,969 cases and 2,290 controls). The overall odds ratio (OR) and the corresponding 95% confidence interval (CI) showed a statistical association between the TSER polymorphism and breast cancer risk under homozygote comparison (2R/2R vs. non-2R/non-2R; OR 1.25; 95% CI 1.04-1.50), allele contrast (2R vs. non-2R; OR 1.09; 95% CI 1.01-1.19) and the recessive model (OR 1.19; 95% CI 1.01-1.39). In the subgroup analysis by ethnicity, a statistically significant increase in cancer risk was found among Caucasians for homozygote comparison (OR 1.31; 95% CI 1.10-1.57), the allele contrast model (OR 1.12; 95% CI 1.02-1.23) and the dominant model (OR 1.40; 95% CI 1.00-1.95). For the TS3'-UTR polymorphism, significant effects were shown using the allele contrast model (OR 1.33; 95% CI 1.03-1.73). However, the TS3'-UTR polymorphism increased breast cancer risk among Asian women (del6 vs. ins6; OR 1.41; 95% CI 1.01-1.98) but not Caucasian women using the homozygote comparison. In conclusion, our meta-analysis suggests that the TSER polymorphism may increase susceptibility to breast cancer in the Caucasian population and the TS3'-UTR polymorphism may be a genetic determinant for developing breast cancer in the Asian population; therefore, ethnic background should be carefully considered in further studies.
Biomarkers for Breast Adenocarcinoma Using In Silico Approaches.
Pandi J, Arulprakasam A, Dhandapani R, Ramanathan S, Thangavelu S, Chinnappan J Evid Based Complement Alternat Med. 2022; 2022:7825272.
PMID: 35280505 PMC: 8913068. DOI: 10.1155/2022/7825272.
Li S, Zhao J, Lv L, Dong D Front Oncol. 2021; 11:762821.
PMID: 34858842 PMC: 8630669. DOI: 10.3389/fonc.2021.762821.
Rahimi Z, Bozorgi Zarini M, Rahimi Z, Shakiba E, Vaisi-Raygani A, Moradi M Iran J Pathol. 2021; 16(1):62-68.
PMID: 33391382 PMC: 7691710. DOI: 10.30699/ijp.2020.117676.2283.
Silva N, Santos A, Nogueira V, Carneiro C, Lima A BMC Cancer. 2020; 20(1):323.
PMID: 32295543 PMC: 7161242. DOI: 10.1186/s12885-020-06811-7.
Coppede F, Stoccoro A, Tannorella P, Migliore L Metabolites. 2019; 9(12).
PMID: 31817852 PMC: 6950100. DOI: 10.3390/metabo9120298.